B.Riley Reiterates Buy Rating on Madrigal Pharmaceuticals (MDGL)

October 29, 2026 4:15 AM EDT Send to a Friend
B.Riley analyst Mayank Mamtani reiterated a Buy rating and $670.00 price target on Madrigal Pharmaceuticals (NASDAQ: MDGL).The analyst comments "We ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login